On the other hand, lymphocyte activation gene-3 (LAG-3) deficient anti-CD19 CAR T cells potently induced robust antigen-specific anti-leukemia impacts in vitro and in NPG mice [152]. This evidence concerns the gene LAG3 and leukemia.